Grail initiated with an Outperform at Baird

Baird initiated coverage of Grail (GRAL) with an Outperform rating and $113 price target Grail is a commercial-stage healthcare company focused on multi-cancer early detection through its Galleri test, which uses a blood draw to screen for more than 50 types of cancer, the analyst tells investors in a research note. The firm believes the company’s upcoming milestones around the NHS-Galleri study readout and potential FDA decision of Galleri could be catalysts for broader adoption.